239 related articles for article (PubMed ID: 38307031)
1. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.
Huang Y; Shao M; Teng X; Si X; Wu L; Jiang P; Liu L; Cai B; Wang X; Han Y; Feng Y; Liu K; Zhang Z; Cui J; Zhang M; Hu Y; Qian P; Huang H
Cell Rep Med; 2024 Feb; 5(2):101400. PubMed ID: 38307031
[TBL] [Abstract][Full Text] [Related]
2. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
3. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
4. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
5. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness.
Chen J; Qiu S; Li W; Wang K; Zhang Y; Yang H; Liu B; Li G; Li L; Chen M; Lan J; Niu J; He P; Cheng L; Fan G; Liu X; Song X; Xu C; Wu H; Wang H
Cell Res; 2023 May; 33(5):341-354. PubMed ID: 36882513
[TBL] [Abstract][Full Text] [Related]
6. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
7. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
9. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
10. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A; Sjöstrand M; Naik J; Mansilla-Soto J; Kefala D; Kladis G; Nianias A; Ruiter R; Poels R; Sarkar I; Patankar YR; Merino E; Reijmers RM; Frerichs KA; Yuan H; de Bruijn J; Stroopinsky D; Avigan D; van de Donk NWCJ; Zweegman S; Mutis T; Sadelain M; Groen RWJ; Themeli M
Sci Transl Med; 2021 Dec; 13(623):eabh1962. PubMed ID: 34878825
[TBL] [Abstract][Full Text] [Related]
11. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR.
Zhou J; Shi F; Luo X; Lei B; Shi Z; Huang C; Zhang Y; Li X; Wang H; Li XY; He X
Int Immunopharmacol; 2024 Jan; 126():111239. PubMed ID: 37979453
[TBL] [Abstract][Full Text] [Related]
12. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
13. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
14. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
15. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
[TBL] [Abstract][Full Text] [Related]
16. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
18. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.
Li H; Li J; Wu J; Shi Z; Gao Y; Song W; Li J; Li Z; Zhang M
Cancer Med; 2023 May; 12(9):10804-10815. PubMed ID: 37039305
[TBL] [Abstract][Full Text] [Related]
19. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
20. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation.
An N; Pan Y; Yang L; Zhang Q; Deng S; Zhang Q; Du X
Mol Pharm; 2023 May; 20(5):2426-2435. PubMed ID: 37021820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
